Provided by Tiger Trade Technology Pte. Ltd.

Alzamend Neuro, Inc

2.11
-0.0600-2.76%
Post-market: 2.110.00000.00%19:49 EST
Volume:18.03K
Turnover:38.44K
Market Cap:8.02M
PE:-0.56
High:2.17
Open:2.13
Low:2.11
Close:2.17
52wk High:12.06
52wk Low:1.88
Shares:3.80M
Float Shares:3.78M
Volume Ratio:0.36
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7631
EPS(LYR):-11.3245
ROE:-144.76%
ROA:-72.71%
PB:1.83
PE(LYR):-0.19

Loading ...

Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate

Benzinga
·
Dec 10

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet

Reuters
·
Nov 20

BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study Conducted At Massachusetts General Hospital

Reuters
·
Nov 19

BUZZ-Alzamend rises after completing mid-stage brain lithium study

Reuters
·
Nov 19

Alzamend Neuro Announces Completion of Clinical Portion of Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

THOMSON REUTERS
·
Nov 19

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

Benzinga
·
Nov 19

Alzamend Neuro Mourns Loss of Director Andrew Woo

TIPRANKS
·
Nov 19

Alzamend Neuro Director Lynne Fahey McGrath Reports Sale of Common Shares

Reuters
·
Oct 25

Alzamend Neuro Inc Issues 361743 Shares of Common Stock Upon Conversion of Series B Preferred

Reuters
·
Oct 10

Director’s Major Stock Sale Shakes Up Alzamend Neuro!

TIPRANKS
·
Oct 01

Alzamend Neuro Inc. Director and 10% Owner Milton C. Ault III Reports Disposal of Common Shares

Reuters
·
Oct 01

Alzamend Neuro Inc. Issues 300,000 Common Shares Upon Conversion of Series B Preferred Stock

Reuters
·
Sep 26

Alzamend Neuro Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Sep 25

U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern Trust

Reuters
·
Sep 25

Alzamend Neuro Inc : Ascendiant Capital Markets Cuts Target Price to $42 From $45

THOMSON REUTERS
·
Sep 25

Director and 10% Owner Milton C III Ault Reports Disposal of Alzamend Neuro Inc. Common Shares

Reuters
·
Sep 24

Maxim Group Sticks to Their Hold Rating for Alzamend Neuro (ALZN)

TIPRANKS
·
Sep 13

Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate

Benzinga
·
Sep 11

Alzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28

Reuters
·
Sep 11

Alzamend Neuro Inc expected to post a loss of 69 cents a share - Earnings Preview

Reuters
·
Sep 06